It's just the way the Mr Market is saying that there's something wrong with this mismatched collection of companies. And it's a bet that the FDA thumbs-down on Friday at worst, or worry of that even with approval the sp will hardly move.
You seem to discount the importance of Medicare picking up the tab for Polaris. 4k is expensive and unless insurance defrays the cost it will not have much traction.
PT44 your post is reasonable and well reasoned. However, there are competitors in genetic testing for molecular diagnostics and targeted therapies which are more mature and larger. Witness MYGN, FMI, GHDX and many others.
Another reason why OPKO stock is falling back is Myriad Genetics recently got Medicare approval for their Polaris prostate cancer test. The BLRI acquisition may well be like the Barron's article pointed out: two weak biopham merging to form a larger weak company.
Laughable--your comment is. Comparing Apple with a strong revenue, accretive earnings, multinational exposure, product development and management teams. Not to mention a $600B market cap with $35B is cash. Look you can be optimistic and a rah-rah for OPK but don't absurd. But then again maybe OPKO has a drug in development for your hysteria.
When we have a ragging market like today, yet the s.p. is basically flat, you have to admit there's a serious problem here and it's not due to China exposure.
Quite possible. Double volume today. At the last earnings report it was mentioned how disappointed that the Medicare approval wasn't done.
Irrespective of the decline in share price, I remain on board and optimistic.
Is par value! In other words the Street values as extremely speculative. For every share that you margin, you must have an equal share in holdings.
This is a ominous metric.
If your entry point was say well below the current sp, then it's easy to don't worry be happy. On the other hand if your b.e. is around $15, then you're losing sleep. Cut your losses or be optimistic ignoring the financial press warning you to stay away. Coupled with earnings losses and an acquisition which may not add significant traction.
Certainly as you say no, even few buyers. That said there are certainly overwhelmingly many sellers. Which leads me to believe that the cognoscenti know.
Actually I doubt that you own those shares. And I think that if you did then either you're a total fool or wealthy enough not to mention what you own. Peter, KMA.
To all others there is something inherently going wrong with OPK. Like a setback that only the boys in the know are acting on.
You're way off on this one. The money in GT is in oncology. Had you read more about FMI you would notice that the leader in chemo drugs,Roche, ought half of FMI outstanding.stock. BRLI will remain a testing lab for.low margin genetic test, and perhaps 4k
It's unlikely that oncologist will depend on BRLI for a treatment guide. Precision medicine is a nascent area just coming into.it's own. I would expect you to know what you rant about. BTW, the acknowledged experts in precision medicine is Foundation Medicine Inc.FMI.
So me the math you clown. Oh right you picked a number
It's disappointing to read the posters who are confidant for the share price to recover but offer no explanation why so little institutional support. Or the Baron's article which calls OPK and BRLI both weak investments. Yep it's easy to be rah-rah when your b.e. point is under the current sp. But for the many retail investors under water they will bail if the shares continue to decline.
I'm unemotional for all my holdings. I sell when I see the sell momentum rising and conversely buy when there is buying enthusiasm. IMO is a dead duck for now. Look at the dreadful lack of institutional interest.
What annoys me on post like yours is that you have no empirical data or fact to support the hypothesis. Is this spades weakness an effect of the acquisition, or is this a further example of a retail stock with little institutional support. Not it will be $20 or $6. It's all b.s..